Status:
UNKNOWN
The Use Of AMH for the Discrimination of Polycystic and Multicystic Ovaries in Nonhyperandrogenic Patients
Lead Sponsor:
Izmir Katip Celebi University
Conditions:
Polycystic Ovary Syndrome
Eligibility:
FEMALE
15-43 years
Brief Summary
AMH is a member of the transforming growth factor family. It is produced by the granulosa cells from 36th weeks of pregnancy.Ovarian granulosa cells are the only source of the antimüllerian hormone. A...
Detailed Description
It is planned to compare the values of FSH/LH, AMH, and 75 gr OGTT between 20 patients diagnosed as PCOS according to the AES-Rotterdam criteria and 20 patients with multicystic ovarian structure but ...
Eligibility Criteria
Inclusion
- Between the ages of 15-43
- \>6 4-9 mm follicles in bilateral ovaries at ultrasonographic examination
- Increased ovarian volume (\>10 ml )
Exclusion
- Hormonal drug users
- Late onset congenital adrenal hyperplasia,androgen secreted ovarian or adrenal tumors
Key Trial Info
Start Date :
February 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2018
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT01878955
Start Date
February 1 2016
End Date
December 31 2018
Last Update
March 1 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.